Cancer drug developer CG Oncology valued at $1.75 bln in strong …

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

CouponFollow Extension

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

17 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

17 hours ago

Jan 25 (Reuters) - Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick …

yahoo.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

17 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

nasdaq.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Yahoo …

17 hours ago

CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

yahoo.com

$1.75
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

17 hours ago

4 days ago · CG Oncology valued at $1.75 bln in strong market debut. CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the …

stockanalysis.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

17 hours ago

Jan 25, 2024 · (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new …

yahoo.com

6%
OFF

CG Oncology Inc | Reuters

17 hours ago

Feb 9, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut

17 hours ago

Jan 25, 2024 · CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq. ...

marketscreener.com

6%
OFF

CG Oncology Valued At $1.75 Billion In Strong Market Debut

17 hours ago

Jan 25, 2024 · (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand …

kelo.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

17 hours ago

Jan 25, 2024 · TradingView India. Cancer drug developer CG Oncology NASDAQ:CGON notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% …

tradingview.com

$1
OFF

Cancer Drug Developer CG Oncology Targets Near $1 Bln Valuation …

17 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

17 hours ago

Jan 18, 2024 · Adds details on company's business, IPO terms in paragraphs 2-6. Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

nasdaq.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

17 hours ago

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

reuters.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

17 hours ago

Jan 23, 2024 · Adds background, IPO detail in paragraphs 2-6. Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. …

nasdaq.com

$306
OFF

UPDATE 2-Drug Developer CG Oncology Targets Up To $306 Mln …

17 hours ago

Jan 23, 2024 · Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

yahoo.com

FAQs about Cancer drug developer CG Oncology valued at $1.75 bln in strong … Coupon?

How much is CG oncology worth?

Jan 25 (Reuters) - Cancer drug developer CG Oncology (CGON.O) notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up pace. ...

Will CG oncology raise $306 million?

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected. ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...

How many shares will CG oncology offer?

CG Oncology did not say how many shares it planned to offer or give an estimated price range. The company plans to use proceeds primarily for supporting operations. The company has applied to list its shares on the Nasdaq Global Market under the ticker CGON. ...

Will CG oncology sell on the NASDAQ?

CG Oncology Inc. on Wednesday filed for an initial public offering to trade on the Nasdaq under the symbol “CGON” with underwriters Morgan Stanley, Goldman Sachs, Cantor and LifeSci Capital. ...

Is CG oncology a good IPO?

Biotech stocks have fallen about 1% so far this year. With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressa... ...